Entity

Time filter

Source Type


Fang M.,Zhejiang University | Xu C.,The General Military Hospital of Beijing PLA | Wu J.,Zhejiang Cancer Hospital | Zhang Y.,Shandong Weifang Peoples Hospital | He C.,Zhejiang University
Journal of Cancer Research and Therapeutics | Year: 2014

Objective: The aim was to detect the consistency of the BRAF gene mutation in peripheral blood and tumor tissue of patients with nonsmall-cell lung cancer and discuss the clinical application value of BRAF gene mutation in peripheral blood.Materials and Methods: Real-time fluorescent quantitative polymerase chain reaction was used to test the tissues in 257 patients of nonsmall-cell lung cancer (NSCLC) and the peripheral blood samples in 318 patients of NSCLC, of which 185 cases of peripheral blood specimens could match the tissue samples, and detected the BRAF gene mutation in them by comparison of mutations consistency in blood and tissue samples, and analyzed the correlation between BRAF gene mutations and clinical characteristics of patients.Results: The BRAF gene mutation rate was 7.23% in peripheral blood of 23 patients with nonsmall-cell lung cancer, and was 5.45% in 14 cancer tissues, the mutation consistency was 80.00% in peripheral blood-tumor tissue matched samples. The consistency was statistically significant (κ =0.710, P = 0.000).Conclusion: The consistency of the BRAF gene mutation in peripheral blood and tissue is high. BRAF gene mutations of peripheral blood could be used for clinical diagnosis and treatment in cases when tissue specimen is hard to get. Source


Zhang X.,BaYi Childrens Hospital of the General Military Hospital of Beijing PLA | Wang H.,The General Military Hospital of Beijing PLA | Shi Y.,BaYi Childrens Hospital of the General Military Hospital of Beijing PLA | Peng W.,BaYi Childrens Hospital of the General Military Hospital of Beijing PLA | And 5 more authors.
Cell Biology International | Year: 2012

BPD (bronchopulmonary dysplasia) is predominantly characterized by persistent abnormalities in lung structure and arrested lung development, but therapy can be palliative. While promising, the use of BMSC (bone marrow-derived mesenchymal stem cell) in the treatment of lung diseases remains controversial. We have assessed the therapeutic effects of BMSC in vitro and in vivo. In vitro co-culturing with injured lung tissue increased the migration-potential of BMSC; and SP-C (surfactant protein-C), a specific marker of AEC2 (type II alveolar epithelial cells), was expressed. Following intraperitoneal injection of BMSC into experimental BPD mice on post-natal day 7, it was found that BMSC can home to the injured lung, express SP-C, improve pulmonary architecture, attenuate pulmonary fibrosis and increase the survival rate of BPD mice. This work supports the notion that BMSC are of therapeutic benefit through the production of soluble factors at bioactive levels that regulate the pathogenesis of inflammation and fibrosis following hyperoxia. © The Author(s) Journal compilation © 2012 International Federation for Cell Biology. Source


Xu C.-W.,The General Military Hospital of Beijing PLA | Wang G.,Dalian University | Wang W.-L.,Dalian University | Wang W.-L.,Inner Mongolia Medical College | And 9 more authors.
Experimental and Therapeutic Medicine | Year: 2015

This study aimed to investigate the association of the mRNA expression of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene with that of thymidylate synthase (TYMS) in non-small cell lung cancer (NSCLC) tissues. Quantitative polymerase chain reaction was used to detect the expression of EML4-ALK fusion gene and TYMS mRNA in 257 cases of NSCLC. The positive rate of EML4-ALK fusion gene was 4.28% in the NSCLC tissues (11/257), and was higher in nonsmokers than in smokers (P<0.05); TYMS mRNA expression was detected in 63.42% (163/257) of cases. An association of the EML4-ALK fusion gene with TYMS expression was detected; a low expression level of TYMS mRNA was observed more frequently when the EML4-ALK fusion gene was present than when it was not detected (P<0.05). In conclusion, patients positive for the EML4-ALK fusion gene in NSCLC tissues are likely to have a low expression level of TYMS, and may benefit from the first-line chemotherapy drug pemetrexed. © 2015, EXPERIMENTAL AND THERAPEUTIC MEDICINE. All Rights Reserved. Source


Xu C.-W.,The General Military Hospital of Beijing PLA | Lin S.,Dalian University | Wang W.-L.,Inner Mongolia Medical College | Gao W.-B.,Dalian University | And 7 more authors.
Experimental and Therapeutic Medicine | Year: 2015

The aim of the present study was to investigate mutation status of the c-Kit gene (KIT) and PDGFRA in patients with a gastrointestinal stromal tumor (GIST). In total, 93 patients with a GIST were included in the study, in which polymerase chain reaction amplification and gene sequencing were used to detect the sequences of exons 9, 11, 13 and 17 in KIT and exons 12 and 18 in PDGFRA. KIT mutations were detected in 64 cases (68.82%), of which exon 11 mutations were detected in 56 cases (60.22%), exon 13 mutations were detected in three cases (3.23%) and one case (1.08%) was shown to have a mutation in exon 17. The most common mutation in exon 11 was a deletion, which accounted for 55.36% (31/56) of the cases, followed by a point mutation observed in 26.79% (15/56) of the cases, while an insertion (tandem repeats) was identified in 14.29% (8/56) of the cases, and 3.57% (2/56) of the exon 11 mutations were deletions associated with a point mutation. The majority of the mutations were heterozygous, with only a few homozygous mutations. Mutational analysis revealed the mutations to be more concentrated in the classic hot zone at the 5'-end, followed by the tandem repeat frame at the 3'-end. In four cases, a mutation was detected in exon 18 of PDGFRA, of which one was associated with a mutation in KIT. The remaining three cases (10.34%, 3/29) were not associated with mutations in KIT and accounted for 37.5% (3/8) of the CD117-negative GIST cases. Therefore, the majority of the GIST cases were characterized by mutations in KIT or PDGFRA, which were directly associated with the disease. Pairs of different mutations in the same exon of KIT, or KIT mutations coupled with pairs of mutations in PDGFRA, were detected in a small number of patients. Imatinib is a small molecule tyrosine kinase inhibitor and is the first line targeted treatment for GIST, resulting in markedly improved survival rates. Thus, gene mutation genotyping may provide inspiration and guidance for imatinib-based targeted cancer therapy. © 2015, Spandidos Publications. All rights reserved. Source


Xu C.-W.,The General Military Hospital of Beijing PLA | Fang M.-Y.,Zhejiang Cancer Hospital | Zhang Y.-P.,Weifang Peoples Hospital | Li Y.,The General Military Hospital of Beijing PLA
Experimental and Therapeutic Medicine | Year: 2014

The aim of this study was to compare quantitative polymerase chain reaction (qPCR) with immunohistochemistry (IHC) for the detection of Her‑2 in gastric cancer, and to investigate the correlation between the expression levels of human epidermal growth factor receptor 2 (Her‑2) and clinical features. Clinical data from 426 cases of gastric cancer were collected. Her‑2 expression levels in cancerous tissue were detected using IHC, and the Her‑2/neu gene expression levels were determined by qPCR. The correlation between the expression level of Her‑2 and clinical features was investigated. The positive expression rate of Her‑2 in cancerous tissue detected using qPCR and IHC was 11.17% (46/412) and 13.38% (57/426), respectively. The positive expression of the Her‑2 protein/gene was significantly correlated with the depth of invasion and lymphatic metastasis, as well as the TNM stage (P<0.05). No significant correlation was identified between positive expression of the Her‑2 protein/gene and tumor location, age, gender, differentiation degree and Lauren classification (P>0.05). The diagnostic consistency was good between the two methods (κ=0.828). The results indicate that the expression of Her‑2/neu is closely associated with the development of gastric cancer. qPCR is a convenient, objective and efficient method, which may be used as an alternative to IHC or fluorescence in situ hybridization for the detection of Her‑2/neu gene. © 2014, Spandidos Publications. All rights reserved. Source

Discover hidden collaborations